Mescia, Federica
 Distribuzione geografica
Continente #
AS - Asia 419
NA - Nord America 311
EU - Europa 298
SA - Sud America 5
AF - Africa 2
Totale 1.035
Nazione #
US - Stati Uniti d'America 306
HK - Hong Kong 187
SG - Singapore 146
IT - Italia 75
DE - Germania 52
TR - Turchia 41
RU - Federazione Russa 39
FI - Finlandia 37
IE - Irlanda 27
GB - Regno Unito 24
CN - Cina 22
ID - Indonesia 13
AT - Austria 10
UA - Ucraina 7
CZ - Repubblica Ceca 5
PL - Polonia 5
CA - Canada 4
NL - Olanda 4
JP - Giappone 3
LT - Lituania 3
BR - Brasile 2
CO - Colombia 2
ES - Italia 2
LU - Lussemburgo 2
LV - Lettonia 2
AE - Emirati Arabi Uniti 1
BE - Belgio 1
CI - Costa d'Avorio 1
EG - Egitto 1
FR - Francia 1
GE - Georgia 1
IL - Israele 1
KH - Cambogia 1
KZ - Kazakistan 1
MX - Messico 1
PE - Perù 1
PT - Portogallo 1
SA - Arabia Saudita 1
SE - Svezia 1
VN - Vietnam 1
Totale 1.035
Città #
Hong Kong 187
Singapore 90
Chandler 53
Istanbul 40
Helsinki 36
Dublin 27
Moscow 19
Romola 18
Nuremberg 16
Jakarta 13
Ashburn 11
Shanghai 10
Beijing 9
London 9
Los Angeles 9
New York 9
Cambridge 8
Princeton 8
Wilmington 7
Brescia 6
Fairfield 6
Frankfurt am Main 6
Woodbridge 6
Bologna 5
Brno 5
Florence 4
Jacksonville 4
Lowicz 4
Vienna 4
Houston 3
Kilburn 3
Allston 2
Amsterdam 2
Barcelona 2
Chiswick 2
Colorno 2
Luxembourg 2
Mantova 2
Milan 2
Modena 2
Munich 2
Ottawa 2
Pereira 2
Reston 2
Riga 2
Seattle 2
St Louis 2
São Paulo 2
The Bronx 2
Torino 2
Toronto 2
Verona 2
Washington 2
Abidjan 1
Almaty 1
Ann Arbor 1
Bergamo 1
Bosio 1
Brussels 1
Cairo 1
Carpenedolo 1
Changsha 1
Clifton 1
Enschede 1
Genova 1
Haifa 1
Hounslow 1
Islington 1
Lappeenranta 1
Lima 1
Mexico City 1
Monza 1
Padova 1
Phnom Penh 1
Pisa 1
Riyadh 1
San Diego 1
Tbilisi 1
Tokyo 1
Turin 1
Viterbo 1
Wandsworth 1
Totale 708
Nome #
Cluster analysis identifies distinct pathogenetic patterns in c3 glomerulopathies/immune complex–Mediated membranoproliferative GN 84
SARS-CoV-2 infection in dialysis and kidney transplant patients: immunological and serological response 51
Monoallelic pathogenic IFT140 variants are a common cause of autosomal dominant polycystic kidney disease–spectrum phenotype 49
Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity 36
The Role of Rituximab in Primary Focal Segmental Glomerular Sclerosis of the Adult 30
Chronic glucocorticoid maintenance treatment is associated with the risk of SARS-CoV-2 infection in patients with systemic lupus erythematosus who received vaccination 29
SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion 28
Coagulation factor V is a T-cell inhibitor expressed by leukocytes in COVID-19 27
Eosinophilic granulomatosis with polyangiitis present and future 27
Effective control of sars-cov-2 transmission between healthcare workers during a period of diminished community prevalence of covid-19 27
B cell receptor repertoire kinetics after SARS-CoV-2 infection and vaccination 26
The impact of hypoxia on B cells in COVID-19 26
Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2 25
Therapies for Membranous Nephropathy: A Tale From the Old and New Millennia 25
Analysis of the B cell receptor repertoire in six immune-mediated diseases 24
Prevention and Therapeutic Management of Bleeding in Dialysis Patients 24
Combined Point-of-Care Nucleic Acid and Antibody Testing for SARS-CoV-2 following Emergence of D614G Spike Variant 24
A thermostable, closed SARS-CoV-2 spike protein trimer 24
An Initial Low-Dose Etelcalcetide Dosing Strategy in Hemodialysis Patients With Moderate Secondary Hyperparathyroidism is Effective and Cost-Saving 24
Sustained post-rituximab B cell depletion is common in ANCA-associated Vasculitis and affected by sex and renal function 24
Impact of Acute Kidney Injury and CKD on Adverse Outcomes in Critically Ill Septic Patients 23
Screening of healthcare workers for SARS-CoV-2 highlights the role of asymptomatic carriage in COVID-19 transmission 23
A patient-centric modeling framework captures recovery from SARS-CoV-2 infection 23
Kidney transplantation from a donor with acute kidney injury: An unexpected outcome 22
Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild disease 21
Predictors of hypogammaglobulinemia in ANCA-associated vasculitis after a rituximab-based induction: a multicentre study 20
SARS-CoV-2 evolution during treatment of chronic infection 20
A critical view on autoantibodies in lupus nephritis: Concrete knowledge based on evidence 19
Single-cell multi-omics analysis of the immune response in COVID-19 19
Clinical Significance of the Cystic Phenotype in Alport Syndrome 19
STEC-HUS, atypical HUS and TTP are all diseases of complement activation 18
Feasibility of MALDI-MSI-Based Proteomics Using Bouin-Fixed Pathology Samples: Untapping the Goldmine of Nephropathology Archives 17
Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report 16
The place of cyclical therapy for the treatment of membranous nephropathy in the era of rituximab 16
The Impact of Anti-SARS-CoV-2 Vaccine in Patients with Systemic Lupus Erythematosus: A Multicentre Cohort Study 16
Treatment goals in ANCA-associated vasculitis: defining success in a new era 15
Congo Red Staining in Digital Pathology: The Streamlined Pipeline for Amyloid Detection Through Congo Red Fluorescence Digital Analysis 14
Autoantibody Profiling and Anti-Kinesin Reactivity in ANCA-Associated Vasculitis 14
Complement lectin pathway activation is associated with COVID-19 disease severity, independent of MBL2 genotype subgroups 14
Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies 14
SARS-CoV-2 spike N-terminal domain modulates TMPRSS2-dependent viral entry and fusogenicity 13
Unmet needs in ANCA-associated vasculitis: Physicians’ and patients’ perspectives 12
Iron dysregulation and inflammatory stress erythropoiesis associates with long-term outcome of COVID-19 11
Proinflammatory cytokines driving cardiotoxicity in COVID-19 9
Proteomic analysis of circulating immune cells identifies cellular phenotypes associated with COVID-19 severity 7
sMR and PTX3 levels associate with COVID-19 outcome and survival but not with Long COVID 7
Totale 1.056
Categoria #
all - tutte 13.380
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.380


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202024 0 0 0 0 0 0 0 6 7 6 2 3
2020/202125 0 4 0 1 6 2 2 1 3 1 5 0
2021/202223 1 2 0 0 0 1 0 0 6 3 3 7
2022/2023174 7 0 5 18 5 59 0 21 37 2 10 10
2023/2024345 15 16 8 40 13 11 10 49 100 7 14 62
2024/2025464 4 10 28 109 73 90 83 67 0 0 0 0
Totale 1.056